The activities of progesterone receptor isoform A and B are differentially modulated by their ligands in a gene-selective manner.
It is known that progesterone receptor (PR) isoform A (PR-A) and isoform B (PR-B) may mediate different effects of progesterone. The objective of this study was to determine if the functions of PR isoforms also vary in response to different PR modulators (PRM). The effects of 7 synthetic PRM were tested in MDA-MB-231 cells engineered to express PR-A, PR-B, or both PR isoforms. The effects of progesterone were similar in cells expressing PR-A or PR-B in which it inhibited growth and induced focal adhesion. On the other hand, synthetic PRM modulated the activity of the PR isoforms differently. RU486, CDB4124, 17alpha-hydroxy CDB4124 and VA2914 exerted agonist activities on cell growth and adhesion via PR-B. Via PR-A, however, these compounds displayed agonist effect on cell growth but induced stellate morphology which was distinct from the agonist's effect. Their dual properties via PR-A were also displayed at the gene expression level: the compounds acted as agonists on cell cycle genes but exhibited antagonistic effect on cell adhesion genes. Introduction of ERalpha by adenoviral vector to these cells did not change PR-A or PR-B mediated effect of PRM radically, but it causes significant cell rounding and modified the magnitudes of the responses to PRM. The findings suggest that the activities of PR isoforms may be modulated by different PRM through gene-specific regulatory mechanisms. This raises an interesting possibility that PRM may be designed to be PR isoform and cellular pathway selective to achieve targeted therapy in breast cancer.
Leo
Joyce C L
JC
School of Biological Sciences, Nanyang Technological University, Singapore.
Lin
Valerie C L
VC
D000256:Adenoviridae / Q000235:genetics; D015153:Blotting, Western; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology; D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D003094:Collagen / Q000378:metabolism; D004338:Drug Combinations; D005260:Female; D005455:Fluorescent Antibody Technique; D006727:Hormone Antagonists / Q000494:pharmacology*; D006801:Humans; D007797:Laminin / Q000378:metabolism; D008024:Ligands; D015735:Mifepristone / Q000494:pharmacology; D009361:Neoplasm Invasiveness / Q000473:pathology; D009649:Norpregnadienes / Q000494:pharmacology; D016133:Polymerase Chain Reaction; D011374:Progesterone / Q000494:pharmacology*; D020033:Protein Isoforms; D011509:Proteoglycans / Q000378:metabolism; D011980:Receptors, Progesterone / Q000819:agonists / Q000037:antagonists & inhibitors / Q000187:drug effects*; D014162:Transfection; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014945:Wound Healing
D004338:Drug Combinations; D006727:Hormone Antagonists; D007797:Laminin; D008024:Ligands; D009649:Norpregnadienes; D020033:Protein Isoforms; D011509:Proteoglycans; D011980:Receptors, Progesterone; C101118:progesterone receptor A; C097314:progesterone receptor B; C059485:matrigel; C461063:telapristone acetate; D015735:Mifepristone; D011374:Progesterone; C094854:ulipristal; D003094:Collagen